NCT02999711 is a Phase 1 clinical trial of REGN3500 in Asthma, sponsored by Regeneron Pharmaceuticals.

Who is sponsoring NCT02999711?

NCT02999711 is sponsored by Regeneron Pharmaceuticals.

What drugs are being tested in NCT02999711?

Interventions in NCT02999711: REGN3500, Placebo.

What condition does NCT02999711 study?

NCT02999711 studies Asthma, Moderate Asthma.

Is NCT02999711 still recruiting?

NCT02999711 is currently completed. Last updated 12 December 2018.

Last reviewed 2018-12-12 · How we verify

NCT02999711

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REGN3500 in Adults With Moderate Asthma

Completed Phase 1 Last updated 12 December 2018

What this trial tests

Phase 1 trial testing REGN3500 in Asthma in 23 participants. Completed in 10 September 2018.

Timeline

3 February 2017

Primary endpoint
30 August 2018

10 September 2018

Quick facts

Lead sponsor	Regeneron Pharmaceuticals
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	other
Enrollment	23
Start date	3 February 2017
Primary completion	30 August 2018
Estimated completion	10 September 2018
Sites	3 locations across United Kingdom

Drugs / interventions tested

REGN3500 — full drug profile →
Placebo

Conditions studied

Asthma — all drugs for Asthma →
Moderate Asthma — all drugs for Moderate Asthma →

Sponsor

Regeneron Pharmaceuticals — full company profile →

Who can join

Adults 18 to 60, any sex, with Asthma or Moderate Asthma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Purpose of this study is to assess the safety and tolerability of multiple ascending subcutaneous doses of REGN3500 to moderate asthmatics.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Phase 2a randomized, placebo-controlled study of anti-IL-33 in peanut allergy.
Chinthrajah S, Cao S, Liu C, Lyu SC, et al · · 2019 · cited 127× · PMID 31723064 · DOI 10.1172/jci.insight.131347
Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics.
Porsbjerg CM, Sverrild A, Lloyd CM, Menzies-Gow AN, et al · · 2020 · cited 113× · PMID 32586879 · DOI 10.1183/13993003.00260-2020
Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: Phase I first-in-human and first-in-patient trials.
Kosloski MP, Kalliolias GD, Xu CR, Harel S, et al · · 2022 · cited 38× · PMID 34523807 · DOI 10.1111/cts.13157
IL33 and Mast Cells-The Key Regulators of Immune Responses in Gastrointestinal Cancers?
Eissmann MF, Buchert M, Ernst M. · · 2020 · cited 31× · PMID 32719677 · DOI 10.3389/fimmu.2020.01389
Targeting the Epithelium-Derived Innate Cytokines: From Bench to Bedside.
Ham J, Shin JW, Ko BC, Kim HY. · · 2022 · cited 21× · PMID 35291657 · DOI 10.4110/in.2022.22.e11
Turning off the alarm - Targeting alarmins and other epithelial mediators of allergic inflammation with biologics.
Albrecht M. · · 2021 · cited 11× · PMID 33615121 · DOI 10.5414/alx02194e
Regulation of Airway Epithelial-Derived Alarmins in Asthma: Perspectives for Therapeutic Targets.
Hansi RK, Ranjbar M, Whetstone CE, Gauvreau GM. · · 2024 · cited 7× · PMID 39457624 · DOI 10.3390/biomedicines12102312

Verify or expand the search:

Other trials of REGN3500

Trials testing the same drug.

NCT03738423 — Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic · Phase 2 · terminated
NCT03736967 — Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-t · Phase 2 · terminated
NCT03112577 — Study of REGN3500 and Dupilumab in Patients With Asthma · Phase 1 · completed

Other recruiting trials for Asthma

Currently open trials in the same condition.

NCT07525375 — A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared t · Phase 2 · recruiting
NCT07536256 — Community Connections Through Native Hawaiian Cultural Values to Strengthen Youth Resilience, Health, and Well-Being · NA · recruiting
NCT07556159 — A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice · recruiting
NCT07282886 — VENTURI (VENTilation Using Respiratory Imaging) · Phase 2 · recruiting
NCT07433569 — A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Differ · Phase 1 · recruiting

Other Regeneron Pharmaceuticals trials

Trials by the same sponsor.

NCT07428369 — A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) · Phase 2, PHASE3 · not yet recruiting
NCT07526116 — A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a Single Dose of REGN22044 in Healthy Adul · Phase 1 · not yet recruiting
NCT07527923 — First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis · Phase 1 · not yet recruiting
NCT07527910 — A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD · Phase 2 · not yet recruiting
NCT07477704 — A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemi · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02999711 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Regeneron Pharmaceuticals
Last refreshed: 12 December 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02999711.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing